Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine.

Liang H, Poncet D, Seydoux E, Rintala ND, Maciel M Jr, Ruiz S, Orr MT.

NPJ Vaccines. 2019 May 28;4:19. doi: 10.1038/s41541-019-0116-6. eCollection 2019.

2.

Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology.

Orr MT, Khandhar AP, Seydoux E, Liang H, Gage E, Mikasa T, Beebe EL, Rintala ND, Persson KH, Ahniyaz A, Carter D, Reed SG, Fox CB.

NPJ Vaccines. 2019 Jan 3;4:1. doi: 10.1038/s41541-018-0094-0. eCollection 2019.

3.

Memory CD4+ T cells enhance B-cell responses to drifting influenza immunization.

Gage E, Van Hoeven N, Dubois Cauwelaert N, Larsen SE, Erasmus J, Orr MT, Coler RN.

Eur J Immunol. 2019 Feb;49(2):266-276. doi: 10.1002/eji.201847852. Epub 2018 Dec 21.

PMID:
30548475
4.

αv Integrins regulate germinal center B cell responses through noncanonical autophagy.

Raso F, Sagadiev S, Du S, Gage E, Arkatkar T, Metzler G, Stuart LM, Orr MT, Rawlings DJ, Jackson SW, Lacy-Hulbert A, Acharya M.

J Clin Invest. 2018 Aug 31;128(9):4163-4178. doi: 10.1172/JCI99597. Epub 2018 Aug 20.

5.

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.

Kramer RM, Archer MC, Orr MT, Dubois Cauwelaert N, Beebe EA, Huang PD, Dowling QM, Schwartz AM, Fedor DM, Vedvick TS, Fox CB.

Int J Nanomedicine. 2018 Jun 26;13:3689-3711. doi: 10.2147/IJN.S159839. eCollection 2018.

6.
7.

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.

Abhyankar MM, Orr MT, Lin S, Suraju MO, Simpson A, Blust M, Pham T, Guderian JA, Tomai MA, Elvecrog J, Pedersen K, Petri WA Jr, Fox CB.

NPJ Vaccines. 2018 Jun 5;3:22. doi: 10.1038/s41541-018-0060-x. eCollection 2018.

8.

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

Larsen SE, Baldwin SL, Orr MT, Reese VA, Pecor T, Granger B, Dubois Cauwelaert N, Podell BK, Coler RN.

Vaccines (Basel). 2018 May 24;6(2). pii: E30. doi: 10.3390/vaccines6020030.

9.

Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.

Seydoux E, Liang H, Dubois Cauwelaert N, Archer M, Rintala ND, Kramer R, Carter D, Fox CB, Orr MT.

J Immunol. 2018 Jul 1;201(1):98-112. doi: 10.4049/jimmunol.1701604. Epub 2018 May 16.

10.

A structure-function approach to optimizing TLR4 ligands for human vaccines.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG.

Clin Transl Immunology. 2016 Nov 2;5(11):e108. eCollection 2016 Nov.

11.

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG.

J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. Epub 2016 Nov 12.

12.

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

Desbien AL, Dubois Cauwelaert N, Reed SJ, Bailor HR, Liang H, Carter D, Duthie MS, Fox CB, Reed SG, Orr MT.

J Immunol. 2016 Dec 1;197(11):4351-4359. Epub 2016 Oct 28.

14.

Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.

Dubois Cauwelaert N, Baldwin SL, Orr MT, Desbien AL, Gage E, Hofmeyer KA, Coler RN.

Eur J Immunol. 2016 Dec;46(12):2719-2729. doi: 10.1002/eji.201646399. Epub 2016 Nov 9.

15.

The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.

Reed SG, Hsu FC, Carter D, Orr MT.

Curr Opin Immunol. 2016 Aug;41:85-90. doi: 10.1016/j.coi.2016.06.007. Epub 2016 Jul 5. Review.

PMID:
27392183
16.

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.

Dubois Cauwelaert N, Desbien AL, Hudson TE, Pine SO, Reed SG, Coler RN, Orr MT.

PLoS One. 2016 Jan 5;11(1):e0146372. doi: 10.1371/journal.pone.0146372. eCollection 2016.

17.

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.

Orr MT, Beebe EA, Hudson TE, Argilla D, Huang PW, Reese VA, Fox CB, Reed SG, Coler RN.

Vaccine. 2015 Nov 27;33(48):6570-8. doi: 10.1016/j.vaccine.2015.10.115. Epub 2015 Nov 3.

18.

Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.

Coler RN, Hudson T, Hughes S, Huang PW, Beebe EA, Orr MT.

J Immunol. 2015 Oct 1;195(7):3190-7. doi: 10.4049/jimmunol.1501118. Epub 2015 Aug 21.

19.

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG.

Clin Transl Immunology. 2015 Apr 10;4(4):e35. doi: 10.1038/cti.2015.6. eCollection 2015 Apr.

20.

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

Orr MT, Windish HP, Beebe EA, Argilla D, Huang PW, Reese VA, Reed SG, Coler RN.

J Infect Dis. 2015 Aug 1;212(3):495-504. doi: 10.1093/infdis/jiv055. Epub 2015 Jan 30.

21.

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.

Desbien AL, Reed SJ, Bailor HR, Dubois Cauwelaert N, Laurance JD, Orr MT, Fox CB, Carter D, Reed SG, Duthie MS.

Eur J Immunol. 2015 Feb;45(2):407-17. doi: 10.1002/eji.201444543. Epub 2014 Dec 3.

22.

Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.

Orr MT, Ireton GC, Beebe EA, Huang PW, Reese VA, Argilla D, Coler RN, Reed SG.

J Immunol. 2014 Sep 15;193(6):2911-8. doi: 10.4049/jimmunol.1401103. Epub 2014 Aug 1.

23.

The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.

Baldwin SL, Reese V, Granger B, Orr MT, Ireton GC, Coler RN, Reed SG.

Clin Vaccine Immunol. 2014 Sep;21(9):1309-13. doi: 10.1128/CVI.00372-14. Epub 2014 Jul 16.

24.

A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.

Orr MT, Beebe EA, Hudson TE, Moon JJ, Fox CB, Reed SG, Coler RN.

PLoS One. 2014 Jan 3;9(1):e83884. doi: 10.1371/journal.pone.0083884. eCollection 2014.

25.

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Orr MT, Kramer RM, Barnes L 5th, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS.

J Control Release. 2014 Mar 10;177:20-6. doi: 10.1016/j.jconrel.2013.12.025. Epub 2013 Dec 29.

26.

Key roles of adjuvants in modern vaccines.

Reed SG, Orr MT, Fox CB.

Nat Med. 2013 Dec;19(12):1597-608. doi: 10.1038/nm.3409. Epub 2013 Dec 5. Review.

PMID:
24309663
27.

Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN.

J Control Release. 2013 Nov 28;172(1):190-200. doi: 10.1016/j.jconrel.2013.07.030. Epub 2013 Aug 9.

28.

Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.

Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN.

J Immunol. 2013 Sep 1;191(5):2514-2525. doi: 10.4049/jimmunol.1301161. Epub 2013 Jul 31.

29.

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, Hudson TE, Shaverdian N, O'Donnell J, Desbien AL, Reed SG, Coler RN.

Eur J Immunol. 2013 Sep;43(9):2398-408. doi: 10.1002/eji.201243124. Epub 2013 Jul 3.

30.

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG.

J Infect Dis. 2013 Apr 15;207(8):1242-52. doi: 10.1093/infdis/jis425. Epub 2012 Aug 13.

31.

Natural killer cell licensing during viral infection.

Orr MT, Lanier LL.

Adv Exp Med Biol. 2011;780:37-44. doi: 10.1007/978-1-4419-5632-3_4. Review.

PMID:
21842363
32.

Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC.

Barao I, Alvarez M, Ames E, Orr MT, Stefanski HE, Blazar BR, Lanier LL, Anderson SK, Redelman D, Murphy WJ.

Blood. 2011 Jun 30;117(26):7032-41. doi: 10.1182/blood-2010-11-316653. Epub 2011 Apr 15.

33.

CD94 is essential for NK cell-mediated resistance to a lethal viral disease.

Fang M, Orr MT, Spee P, Egebjerg T, Lanier LL, Sigal LJ.

Immunity. 2011 Apr 22;34(4):579-89. doi: 10.1016/j.immuni.2011.02.015.

34.

Development and function of CD94-deficient natural killer cells.

Orr MT, Wu J, Fang M, Sigal LJ, Spee P, Egebjerg T, Dissen E, Fossum S, Phillips JH, Lanier LL.

PLoS One. 2010 Dec 3;5(12):e15184. doi: 10.1371/journal.pone.0015184.

35.

Natural killer cell education and tolerance.

Orr MT, Lanier LL.

Cell. 2010 Sep 17;142(6):847-56. doi: 10.1016/j.cell.2010.08.031. Review.

36.

Natural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus.

Orr MT, Beilke JN, Proekt I, Lanier LL.

Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15844-9. doi: 10.1073/pnas.1010685107. Epub 2010 Aug 23.

37.

Inhibitory Ly49 receptors on mouse natural killer cells.

Orr MT, Lanier LL.

Curr Top Microbiol Immunol. 2011;350:67-87. doi: 10.1007/82_2010_85. Review.

PMID:
20680808
38.

'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection.

Orr MT, Murphy WJ, Lanier LL.

Nat Immunol. 2010 Apr;11(4):321-7. doi: 10.1038/ni.1849. Epub 2010 Feb 28.

39.

Psychosocial impact of periodontal disease and its treatment with 24-h root surface debridement.

Jowett AK, Orr MT, Rawlinson A, Robinson PG.

J Clin Periodontol. 2009 May;36(5):413-8. doi: 10.1111/j.1600-051X.2009.01384.x.

PMID:
19419442
40.

Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection.

Orr MT, Sun JC, Hesslein DG, Arase H, Phillips JH, Takai T, Lanier LL.

J Exp Med. 2009 Apr 13;206(4):807-17. doi: 10.1084/jem.20090168. Epub 2009 Mar 30.

41.

CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I.

Orr MT, Mathis MA, Lagunoff M, Sacks JA, Wilson CB.

Cell Host Microbe. 2007 Sep 13;2(3):172-80.

43.

Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice.

Orr MT, Edelmann KH, Vieira J, Corey L, Raulet DH, Wilson CB.

PLoS Pathog. 2005 Sep;1(1):e7. Epub 2005 Sep 30.

44.

T cell receptor revision does not solely target recent thymic emigrants.

Cooper CJ, Orr MT, McMahan CJ, Fink PJ.

J Immunol. 2003 Jul 1;171(1):226-33.

45.

The efficacy of practical participation in undergraduate dental education.

Russell MD, Bill JM, Orr MT.

J Dent. 1996 Jan-Mar;24(1-2):137-9.

PMID:
8636485
46.

The need and unmet need for infertility services in the United States.

Henshaw SK, Orr MT.

Fam Plann Perspect. 1987 Jul-Aug;19(4):180-3, 186.

PMID:
3678484
47.
48.

The provision of sterilization services by private physicians.

Orr MT, Forrest JD, Johnson JH, Tolman DL.

Fam Plann Perspect. 1985 Sep-Oct;17(5):216-20. Erratum in: Fam Plann Perspect 1986 Jan-Feb;18(1):26.

PMID:
3916183
49.

The availability of reproductive health services from U.S. private physicians.

Orr MT, Forrest JD.

Fam Plann Perspect. 1985 Mar-Apr;17(2):63-9.

PMID:
3842655
50.

Sex education: an overview of current programs, policies, and research.

Kenney AM, Orr MT.

Phi Delta Kappan. 1984 Mar;65(1):491-6. No abstract available.

PMID:
12339949

Supplemental Content

Support Center